TT-232

• Description :

  TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent[1][2][4].

• Product Name Alternative :

  CAP-232; TLN-232

• UNSPSC :

  12352209

• Target :

  Somatostatin Receptor

• Type :

  Peptides

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/tt-232.html

• Purity :

  98.72

• Solubility :

  H2O : < 0.1 mg/mL (ultrasonic)

• Smiles :

  O=C(N[C@H](C(N[C@@H]1C(N[C@H](C(N)=O)[C@H](O)C)=O)=O)CCCCN)[C@H](NC([C@@H](NC([C@H](CSSC1)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC(C=C3)=CC=C3O)=O)CC4=CNC5=CC=CC=C45

• Molecular Formula :

  C45H58N10O9S2

• Molecular Weight :

  947.13

• References & Citations :

  [1]Szende B, et al. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Anticancer Drugs. 2003 Sep;14 (8) :585-8. |[2]Kéri G, et al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci U S A. 1996 Oct 29;93 (22) :12513-8. |[3]Tejeda M, et al. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. Anticancer Res. 2005 Jan-Feb;25 (1A) :325-30. |[4]Pintér E, et al. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366 (2) :142-50.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

• Scientific Category :

  Peptides

• Clinical Information :

  Phase 2

• Isoform :

  SSTR1; SSTR4

• CAS Number :

  [147159-51-1]